CLINICAL TRIALS PROFILE FOR ACCUPRIL

All Clinical Trials for Accupril

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00269243 ↗	Management With Accupril Post Bypass Graft	Completed	Pfizer	Phase 4	1999-11-01	Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to reduce the risk of cardiovascular events in some groups of patients following myocardial infarction. This study is designed to test whether early initiation (≤7 days) of an ACE inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to quinapril, target dose 40 mg daily or placebo, followed up to 43 months.
NCT00269243 ↗	Management With Accupril Post Bypass Graft	Completed	Montreal Heart Institute	Phase 4	1999-11-01	Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to reduce the risk of cardiovascular events in some groups of patients following myocardial infarction. This study is designed to test whether early initiation (≤7 days) of an ACE inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to quinapril, target dose 40 mg daily or placebo, followed up to 43 months.
NCT00438113 ↗	Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF	Completed	Nova Scotia Health Research Foundation	Phase 4	2009-12-01	Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.
NCT00438113 ↗	Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF	Completed	Nova Scotia Health Authority	Phase 4	2009-12-01	Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.
NCT00649103 ↗	Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-12-01	The objective of this study was to investigate the bioequivalence of Mylan quinapril hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose under fasting conditions.
NCT00649649 ↗	Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-12-01	The objective of this study was to investigate the bioequivalence of Mylan quinapril hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose under fed conditions.
NCT00795262 ↗	Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension	Completed	InVasc Therapeutics, Inc.	N/A	2008-07-01	We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.

Clinical Trial Conditions for Accupril

Condition Name

Condition Name for Accupril
Intervention	Trials
Healthy	2
Hypertension	2
Hypotension on Induction	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for Accupril
Intervention	Trials
Hypotension	1
Hypertension	1
Diabetes Mellitus	1
Atrial Fibrillation	1

Clinical Trial Locations for Accupril

Trials by Country

Trials by Country for Accupril
Location	Trials
United States	4
Canada	1

Trials by US State

Trials by US State for Accupril
Location	Trials
North Dakota	2
Nebraska	1
Georgia	1

Clinical Trial Progress for Accupril

Clinical Trial Phase

Clinical Trial Phase for Accupril
Clinical Trial Phase	Trials
Phase 4	3
Phase 1	2
N/A	1

Clinical Trial Status

Clinical Trial Status for Accupril
Clinical Trial Phase	Trials
Completed	6

Clinical Trial Sponsors for Accupril

Sponsor Name

Sponsor Name for Accupril
Sponsor	Trials
Mylan Pharmaceuticals	2
Nova Scotia Health Authority	1
InVasc Therapeutics, Inc.	1

Sponsor Type

Sponsor Type for Accupril
Sponsor	Trials
Industry	4
Other	4